Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists.

[1]  E. M. Nakamura-Palacios,et al.  The Pharmacology of SR 141716A: A Review , 2006 .

[2]  J. Lange,et al.  Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists. , 2005, Journal of medicinal chemistry.

[3]  J. Chen,et al.  Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists. , 2005, Bioorganic & medicinal chemistry letters.

[4]  G. Scriba,et al.  Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation. , 2005, Journal of medicinal chemistry.

[5]  R. Pertwee,et al.  Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. , 2005, Life sciences.

[6]  J. Chen,et al.  Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists. , 2005, Bioorganic & medicinal chemistry letters.

[7]  Shuxian Hu,et al.  Synthetic cannabinoid WIN55,212‐2 inhibits generation of inflammatory mediators by IL‐1β‐stimulated human astrocytes , 2005, Glia.

[8]  Roger A. Smith,et al.  Recent advances in the research and development of CB1 antagonists. , 2005, IDrugs : the investigational drugs journal.

[9]  L. M. Lima,et al.  Bioisosterism: a useful strategy for molecular modification and drug design. , 2005, Current medicinal chemistry.

[10]  N. Campillo,et al.  Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study. , 2005, European journal of medicinal chemistry.

[11]  R. Hampson,et al.  Cannabinoid physiology and pharmacology: 30 years of progress , 2004, Neuropharmacology.

[12]  J. Jenkins,et al.  A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes. , 2004, Journal of medicinal chemistry.

[13]  S. Woods,et al.  Pharmaceutical approaches to the treatment of obesity. , 2004, Drug discovery today.

[14]  Donald L. Hertzog.  Recent advances in the cannabinoids , 2004 .

[15]  A. Barbáchano,et al.  Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study , 2004, Synapse.

[16]  B. Cravatt,et al.  Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. , 2004, Human molecular genetics.

[17]  P. Soubrié,et al.  SR147778 [5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a New Potent and Selective Antagonist of the CB1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization , 2004, Journal of Pharmacology and Experimental Therapeutics.

[18]  L. Petrocellis,et al.  The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.

[19]  S. Miller,et al.  Towards cannabis and cannabinoid treatment of multiple sclerosis. , 2004, Drugs of today.

[20]  Paul F. Smith.  Medicinal cannabis extracts for the treatment of multiple sclerosis. , 2004, Current opinion in investigational drugs.

[21]  J. Lange,et al.  Recent advances in CB1 cannabinoid receptor antagonists. , 2004, Current opinion in drug discovery & development.

[22]  I. McGregor,et al.  Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. , 2004, Endocrinology.

[23]  H. Meltzer,et al.  Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. , 2004, The American journal of psychiatry.

[24]  F. Rodríguez de Fonseca,et al.  Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif. , 2004, Journal of medicinal chemistry.

[25]  Antti Poso,et al.  Development of a 3D model for the human cannabinoid CB1 receptor. , 2004, Journal of medicinal chemistry.

[26]  A. Argiolas,et al.  Antagonism of cannabinoid CB1 receptors in the paraventricular nucleus of male rats induces penile erection , 2004, Neuroscience Letters.

[27]  J. R. Fernández,et al.  Rimonabant Sanofi-Synthélabo. , 2004, Current opinion in investigational drugs.

[28]  S. Black.  Cannabinoid receptor antagonists and obesity. , 2004, Current opinion in investigational drugs.

[29]  W. Campbell,et al.  Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. , 2004, Molecular pharmacology.

[30]  Teresa Y. Phillips,et al.  Potent imidazole and triazole CB1 receptor antagonists related to SR141716. , 2004, Bioorganic & medicinal chemistry letters.

[31]  L. Petrocellis,et al.  The endocannabinoid system: a general view and latest additions , 2004, British journal of pharmacology.

[32]  C. Fowler.  Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. , 2004, Trends in pharmacological sciences.

[33]  V. Arango,et al.  Upregulation of CB1 receptors and agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide victims , 2004, Molecular Psychiatry.

[34]  J. Lange,et al.  Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. , 2004, Journal of medicinal chemistry.

[35]  R. Pertwee.  Novel Pharmacological Targets for Cannabinoids , 2004 .

[36]  B. Platt,et al.  Cannabinoids: mechanisms and therapeutic applications in the CNS. , 2003, Current medicinal chemistry.

[37]  M. Costanzi,et al.  Cannabinoids and memory: animal studies. , 2003, Current drug targets. CNS and neurological disorders.

[38]  D. Lovinger,et al.  G Protein-coupled Endothelial Receptor for Atypical Cannabinoid Ligands Modulates a Ca2+-dependent K+ Current* , 2003, Journal of Biological Chemistry.

[39]  Mary E Abood,et al.  An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. , 2003, Journal of medicinal chemistry.

[40]  M. Eder,et al.  CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity , 2003, Science.

[41]  C. Newton,et al.  The cannabinoid system and immune modulation , 2003, Journal of leukocyte biology.

[42]  Potentiation of penile erection and yawning responses to apomorphine by cannabinoid receptor antagonist in rats , 2003, Neuroscience Letters.

[43]  J. Leander,et al.  SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task. , 2003, European journal of pharmacology.

[44]  T. Bisogno,et al.  Possible endocannabinoid control of colorectal cancer growth. , 2003, Gastroenterology.

[45]  G. von Heijne,et al.  Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail. , 2003, Molecular pharmacology.

[46]  D. Cockayne,et al.  Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Flachskamm,et al.  The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. , 2003, The Journal of clinical investigation.

[48]  Patricia H Reggio,et al.  Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. , 2003, Current pharmaceutical design.

[49]  P. Casti,et al.  Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor , 2003, Journal of Pharmacology and Experimental Therapeutics.

[50]  L. Panlilio,et al.  The Cannabinoid CB1 Antagonist N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) Differentially Alters the Reinforcing Effects of Heroin under Continuous Reinforcement, Fixed Ratio, and Progressive Ratio Schedules of Drug Self-Administration in Rats , 2003, Journal of Pharmacology and Experimental Therapeutics.

[51]  T. Groblewski,et al.  Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models , 2003, The European journal of neuroscience.

[52]  C. George,et al.  Structure elucidation of a novel ring‐constrained biaryl pyrazole CB1 cannabinoid receptor antagonist , 2003 .

[53]  K. Mackie,et al.  Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration , 2003, The Journal of Neuroscience.

[54]  A. Hoffman,et al.  Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. , 2003, Journal of medicinal chemistry.

[55]  Giovanni Loriga,et al.  Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1and CB2 cannabinoid receptors. , 2003, Bioorganic & medicinal chemistry.

[56]  William J Welsh,et al.  Homology model of the CB1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction , 2003, Biopolymers.

[57]  J. Ludovic Croxford,et al.  Therapeutic Potential of Cannabinoids in CNS Disease , 2003, CNS drugs.

[58]  B. Martin,et al.  Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. , 2002, Chemistry and physics of lipids.

[59]  C. Bass,et al.  SR-141716A-induced stimulation of locomotor activity A structure–activity relationship study , 2002, Pharmacology Biochemistry and Behavior.

[60]  D. Lynch,et al.  N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. , 2002, Molecular pharmacology.

[61]  P. Cowley,et al.  Recent advances in the cannabinoids , 2002 .

[62]  G. Perrault,et al.  SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats , 2002, Behavioural pharmacology.

[63]  J. Lange,et al.  Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. , 2002, Chemical & pharmaceutical bulletin.

[64]  Herbert H Seltzman,et al.  Synthesis and Structure−Activity Relationships of Amide and Hydrazide Analogues of the Cannabinoid CB1 Receptor Antagonist N-(Piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) , 2002 .

[65]  R. Nicoll,et al.  Endocannabinoid Signaling in the Brain , 2002, Science.

[66]  L. Parsons,et al.  Ethanol, endocannabinoids, and the cannabinoidergic signaling system. , 2002, Alcoholism, clinical and experimental research.

[67]  William J Welsh,et al.  Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor. , 2002, Journal of medicinal chemistry.

[68]  T. Freund,et al.  Evidence for presynaptic cannabinoid CB(1) receptor-mediated inhibition of noradrenaline release in the guinea pig lung. , 2001, European journal of pharmacology.

[69]  R. Capasso,et al.  Cannabinoid CB1‐receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation , 2001, British journal of pharmacology.

[70]  A. Sanyal,et al.  Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis , 2001, Nature Medicine.

[71]  Z. Vogel,et al.  2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[72]  M. Grier,et al.  Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation. , 2001, The Journal of pharmacology and experimental therapeutics.

[73]  A. Howlett,et al.  Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. , 2000, Biochemical pharmacology.

[74]  A. Finazzi-Agro’,et al.  Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage , 2000, The Lancet.

[75]  R. Pertwee,et al.  Cannabinoids control spasticity and tremor in a multiple sclerosis model , 2000, Nature.

[76]  R. Mechoulam,et al.  HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[77]  S. Yu,et al.  3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. , 1999, Bioorganic & medicinal chemistry.

[78]  J. Huffman,et al.  Cannabimimetic indoles, pyrroles and indenes. , 1999, Current medicinal chemistry.

[79]  M. Rinaldi-Carmona,et al.  The development of cannabinoid antagonists. , 1999, Current medicinal chemistry.

[80]  A. Makriyannis,et al.  Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. , 1999, Journal of medicinal chemistry.

[81]  B. Thomas,et al.  The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes. , 1998, Journal of medicinal chemistry.

[82]  C. Newton,et al.  Cannabinoid receptors and immunity. , 1998, Immunology today.

[83]  P. Casellas,et al.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. , 1998, The Journal of pharmacology and experimental therapeutics.

[84]  R. Mechoulam,et al.  Towards cannabinoid drugs--revisited. , 1998, Progress in medicinal chemistry.

[85]  R. Pertwee.  Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[86]  B. Martin,et al.  Cannabis: pharmacology and toxicology in animals and humans. , 1996, Addiction.

[87]  T. Bonner,et al.  A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. , 1996, Molecular pharmacology.

[88]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[89]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[90]  R. Mechoulam,et al.  Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .